To the Editor We carefully read the article by Khan and colleagues.1 The authors evaluated the mortality risk and risk of suicide among adult patients with a diagnosis of schizophrenia, depression, bipolar disorder, anxiety disorders, or attention-deficit/hyperactivity disorder participating in clinical trials conducted by pharmaceutical companies. The trials were reported to the US Food and Drug Administration for approval to market pharmaceutical agents and to evaluate whether psychopharmacological agents worsen this risk.
Nordentoft M, Laursen TM. Was Risk of Suicide Underestimated?. JAMA Psychiatry. 2014;71(6):716. doi:10.1001/jamapsychiatry.2014.148